Introduction Urine is the specimen of choice for CT and NG molecular testing from males and many of the next generation testing platforms are not FDA approved for use with urethral swabs. Urethral swabs remain valuable in research settings that may require that the specimen is collected in a manner preserving organism viability. The goal of this study was to assess the Abbott m2000 Realtime (m2000), and Roche COBAS 4800 (c4800) systems for the identification of CT and NG in urethral swabs collected in chlamydia transport medium (CTM). Methods Archived male urethral swabs collected in CTM from STD clinic attendees were tested. These specimens were originally tested for CT and NG on a platform FDA-approved for urethral swabs collected in CTM (Roche COBAS Amplicor, (cAMP)).Two-hundred ml of CTM was added into each manufacturer's collection device. This was subsequently tested on the m2000 and c4800 systems according to the manufacturer's instructions. CT and NG results obtained from each platform were compared to the original cAMP results to determine sensitivity and specificity. Agreement between platforms was measured by calculating the kappa coefficient. Results One hundred urethral swab specimens were available for testing (28 CT and 25 NG positives). When compared to results obtained with the cAMP, the sensitivity and specificity of the m2000 for the detection of CT was 100% and 98.6%, respectively; the sensitivity and specificity on the c4800 was 96.4% and 98.6%. For NG, the sensitivity and specificity of the m2000 assay was 100% and 98.7%; the c4800 assay was 100% sensitive and specific. Agreement was excellent for both platforms when compared to cAMP with kappa scores of >0.95 for CT and >0.97 for NG. Conclusion The m2000 and c4800 platforms have similar performance characteristics to cAMP for the detection of CT and NG using urethral swabs in CTM. This study will provide investigators with additional options when designing protocols that require the preservation and ability to recover viable organisms from men.
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HPV IS ASSOCIATED WITH AN ALTERED METABOLOMIC PROFILE IN THE VAGINAL TRACT Introduction Recent studies have reported associations between bacterial vaginosis (BV) and cervicovaginal HPV. To obtain further insight into this relationship, we examined the vaginal microbiota and metabolome of women who were HPV+ and HPV-. Methods Thirty-nine women self-collected mid-vaginal swabs that were profiled for bacterial composition by 16S rRNA gene amplicon sequencing, metabolites by both GC/MS and LC/MS-based metabolomics and 37 types of HPV DNA with the Roche HPV Linear Array genotyping test. Data were analysed by multiple linear regression controlling for confounding factors, as well as principal components analysis, partial least squares discriminatory analysis and linear discriminant analyses. All reported results have an adjusted p-value (qvalue) <0.05. Results Vaginal microbiota were clustered into community state types CST-I (L. crispatus-dominated), CST-III (L. iners-dominated) and CST-IV (low-Lactobacillus/BV-associated taxa). Overall, HPV+ women had higher polyamine and phospholipid concentrations than HPV-women in a model which controlled for CST and smoking status. Significant differences in metabolomic profiles of HPV+ and HPV-women were also evident in each stratum of CST. Among women who were CST-III, HPV+ women had higher concentrations of biogenic amines and glycogen-related metabolites compared to HPVwomen. Within CST-IV, HPV+ women had lower concentrations of glutathione, glycogen, and phospholipid-related metabolites than HPV-women. Women with high-risk HPV strains had lower concentrations of amino acids, lipids and peptides compared to women who were hrHPV-. Conclusion Detection of HPV was associated with altered vaginal concentrations of biogenic amines, glutathione and lipidrelated metabolites. Reduced glutathione and oxidised glutathione have known associations with HPV and may be representative of increased oxidative stress and total glutathione depletion. Elucidating a causal relationship between microbial metabolites associated with increased oxidative stress and HPV infection warrants further investigation.
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Introduction Bacterial vaginosis (BV) is a polymicrobial syndrome characterised by the decrease in Lactobacilli and an increase of anaerobic bacteria, mainly G. vaginalis a Grampositive coccobacillus that is isolated in up to 98% of BV cases. This bacteria produces differents virulence factors like sialidase, succinate, biofilm formation, phospholipase C, and vaginolysin (VLY). The VLY is a protein of 56 kDa that belongs to the family of cholesterol-dependent cytolysins, the function of this protein is the cellular lysis of erythrocytes and epithelial cells through the binding to the CD59 receptor and cholesterol present in cell membranes. The production of a policlonal antibody agains VLY will allow the study of this cytolysin in the pathogenesis of Gardnerella vaginalis in the vaginal tract. Methods We use as antigen the ATCC 14018 of G. vaginalis wich was obtained from a extract of total proteins by electrophoresis. The band corresponding to the molecular weight of the VLY (56 kDa) was cut, macerated and resuspended in PBS. Two New Zealand rabbits were immunised for 6 weeks,
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